Biotech firms engineer tobacco to mass-produce psychedelics, obscuring colonial extraction of natural compounds and therapeutic commodification risks

Indigenous communities have stewarded psychedelic plants for millennia, using them in sacred, communal, and therapeutic contexts that emphasize reciprocity with nature. The biotech industry’s appropriation of these compounds—without recognition of Indigenous knowledge systems or consent—replicates colonial patterns of extraction and erasure. Traditional practices, such as the Shipibo-Conibo’s use of ayahuasca, involve intricate ecological and spiritual protocols that are incompatible with industrialized production. This systemic oversight reduces complex cultural practices to mere chemical precursors for pharmaceutical profit.

The history of psychedelic plants is intertwined with colonial violence, from the suppression of peyote use by Christian missionaries to the patenting of turmeric by Western pharmaceuticals. The 20th-century criminalization of psychedelics in the West was driven by racialized fears and corporate interests, not scientific evidence. The current biotech push mirrors earlier waves of plant-based medicine commodification, such as the 19th-century patenting of coca leaves by European chemists. This pattern reflects a recurring cycle of Indigenous knowledge extraction followed by corporate monopolization.

In West African traditions, *iboga* is used in Bwiti ceremonies to facilitate spiritual growth and healing, with the plant’s cultivation governed by strict ecological and ethical codes. In the Andes, *San Pedro* cactus is revered as a living deity, with its use embedded in communal rituals that emphasize balance and harmony. The Western biotech approach, by contrast, treats these plants as raw materials for chemical synthesis, stripping them of their cultural and spiritual significance. This cross-cultural comparison reveals how psychedelics are framed differently—as sacred entities versus commodified molecules—depending on the cultural lens.

Psychedelics like psilocybin and DMT interact with serotonin receptors (e.g., 5-HT2A) to induce neuroplasticity, which has shown promise in treating depression, PTSD, and addiction. However, the biotech approach to production risks oversimplifying the entourage effect, where other plant compounds modulate the therapeutic experience. Synthetic production may lack the complex molecular interactions found in whole-plant preparations, which are often integral to traditional use. Additionally, the ecological impacts of tobacco cultivation—such as soil depletion and pesticide use—pose significant sustainability challenges for large-scale production.

Psychedelics have long been used in art and spirituality to expand consciousness, from the visionary art of Alex Grey to the communal rituals of the Native American Church. The tobacco plant itself holds deep spiritual significance in many Indigenous cultures, often used as a sacred offering or medicine. By reducing these compounds to industrial products, the biotech narrative strips away their role as catalysts for artistic and spiritual exploration. This loss of cultural and creative context risks reducing psychedelics to mere pharmaceutical tools, devoid of their transformative potential.

If biotech production scales, it could lead to corporate monopolies on psychedelic therapies, pricing out marginalized communities who have historically used these plants. The focus on tobacco—a crop tied to deforestation and health harms—could exacerbate ecological crises while failing to address the root causes of mental health disparities. Alternative models, such as community-led cultivation of traditional plants, could offer more sustainable and culturally grounded solutions. Scenario planning must consider the ethical implications of commodifying sacred plants and the potential for reinforcing systemic inequities.

Indigenous healers, who have preserved and transmitted knowledge of psychedelic plants for generations, are sidelined in favor of Western scientists and corporations. Communities of color, who have been disproportionately targeted by the war on drugs, face barriers to accessing psychedelic therapies even as they are commodified. The biotech narrative ignores the voices of those who have used these plants in healing ceremonies for centuries, instead framing them as passive beneficiaries of corporate innovation. This erasure perpetuates historical injustices and reinforces power imbalances in global health.